Document Type



Media is loading

Publication Date



Overall Goals and Objectives:

1. List determinants of prognosis in Pulmonary Arterial Hypertension (PAH).

2. Recognize echocardiographic parameters of Right Venticular Function.

3. Become familiar with the assessment of exercise tolerance in Pulmonary Arterial Hypertension (PAH).

4. Learn about the newest medications for Pulmonary Arterial Hypertention (PAH).


Dr. Michael Scharf joined Thomas Jefferson's Division of Pulmonary and Critical Care Medicine in February 2009 as a Clinical Associate Professor of Medicine. He completed his internal medicine residency at the Montefiore Medical Center in the Bronx, New York and fellowship in pulmonary and critical care medicine at the Hospital of the University of Pennsylvania and Temple University Hospital. At the Deborah Heart and Lung Center in Browns Mills, New Jersey where he served as an attending physician in the pulmonary division and director of the pulmonary function lab, he founded and directed their pulmonary hypertension program.

At Jefferson, he servers as the Director of the Pulmonary Vascular Disease Program and each week, evaluates patients for pulmonary hypertension at the Jefferson Heart Institute. His patients receive PAH-specific medicines under his direction, including parenteral and inhaled prostacyclins and oral therapies. Dr. Scharf also evaluates and treats patients with general pulmonary issues, serving as the medical director of the pulmonary outpatient practice.

Dr. Scharf will discuss using goal-oriented therapy to treat patients with PAH.